HTGF invests in Predemtec

The seed investment will be used to support initial testing and to create a marketable product. The company also stated it would expand the scope of the tests towards early diagnosis.

According to Predemtec, approximately 36 million people worldwide suffer from dementia and two thirds of all cases are Alzheimer's disease.

Dementia diagnosis and care has already seen significant private equity investment. In 2010, HTGF took part in a series-C funding round for drug company Galanthos Pharma. The Mainz-based pharmaceutical company develops medication for neurodegenerative diseases and focuses on Alzheimer's.

The deal marks HTGF's seventh investment this month and is its fourth newly backed company. It also completed an exit earlier this week, selling its stake in online marketing service MeinProspekt to consumer information portal kaufDA.

Company
Founded in September 2011, Predemtec has developed a test that diagnoses Alzheimer's disease with a specificity and sensitivity of more than 90% using immunological detection of six different blood biomarkers. When detected early, therapies can be effectively implemented to delay the onset of the illness.

Headquartered in Hennigsdorf, the company has patented its biomarkers, and clinical trials for the early diagnosis of Alzheimer's are underway. According to the company, Alzheimer's dementia begins 10-15 years before the first clinical symptoms appear, which are masked by the central nervous system's compensation mechanisms.

People
CEO Patrick Scotton and managing director Annegret Feuerhelm-Heidl are co-founders of Predemtec. Martin Pfister is senior investment manager at HTGF.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• High-Tech Gründerfonds